Company Profile

A preclinical-stage biotechnology company addressing novel therapeutics for major unmet medical needs - especially high mortality cancers - Sapience Therapeutics is focused on discovery and development of peptide-based therapeutics for previously ‘undruggable’ targets: high mortality cancers. The firm's drug candidates target protein-protein interactions (“PPIs”) understood to be responsible either for making cells cancerous or for dampening the immune response against tumors. Considered ‘undruggable’ due to their being PPIs resident inside cell - making them difficult to treat with small molecule drugs such as chemotherapies (known not to be capable disrupting PPIs) or newer biologic-based drugs (eg monoclonal antibodies) - too big to enter the cell - the Sapience effort is to combine the best features of these two drug classes by developing cell-penetrating peptides that can enter cells and disrupt these protein-protein interactions.